The RCM Bottleneck

Most healthcare buyers walk past revenue cycle management because it looks unglamorous. Billing, coding, denials, A/R follow-up. The work is invisible to patients and to most physicians, which is exactly why it's mispriced. Inside the bottleneck sits some of the most durable, contracted, recession-resistant cash flow in healthcare services. The specialty layer of that market, where generalist billing companies systematically underperform, is where the real acquisition opportunity lives.

This is the thesis behind Crownestone Health Partners' interest in specialty RCM as a Deal Zero target sector.

The macro is louder than most operators realize

Initial claim denials hit 11.8% in 2024, up from 10.2% a few years earlier. Medicare Advantage denials spiked 4.8% year over year. In the 2026 Guidehouse and HFMA survey, 88% of executives said disagreements over claims were preventing payment, 74% reported rising prior authorization delays, and nearly half said they were losing 3% to 4% of net patient revenue to denials, underpayments, or timely filing limits. RCM teams are now spending 51 to 75 hours per week on denial work alone.

That is not a back-office problem. That is a margin problem hiding in plain sight.

That is not a back-office problem. That is a margin problem hiding in plain sight.

The market is responding. The global RCM industry was measured at roughly $85 billion in 2025, forecast to compound at 11.5% through 2034, and two-thirds of providers now outsource all or part of their revenue cycle. The demand curve is bending toward partners who can reduce denials, accelerate cash, and deliver clean claim rates above 95%. Most generalist billing shops cannot.

Where the bottleneck sits

A specialty RCM thesis sharpens when you stop looking at "billing" as one workflow and start looking at four distinct failure modes that quietly compound into margin loss.

First, denial root-cause illiteracy. Generalist billing companies treat denials as a recovery problem. Specialty operators treat them as a prevention problem. The difference is which payer behaviors, CPT codes, modifier rules, and documentation patterns the team actually understands. Run an ASC, anesthesia, orthopedic, or pain management book through a generalist platform and you get "silent" denials: claims that pay but pay incorrectly, downcoded line items, bundled-away modifiers, underpayments that never get appealed because nobody surfaced them as a pattern. The giveaway is repetition, and most generalist shops cannot see it.

Second, A/R aging that hides beneath the average. Days in A/R is a vanity metric unless it's broken down by payer, by procedure, and by aging bucket. The practices that get acquired at distressed multiples almost always have one or two payers driving 70% of aged A/R, with no internal contract review function escalating those disputes. A buyer who rebuilds that function in the first 90 days unlocks immediate cash and improved net collection rates without touching headcount.

Third, payer mix concentration. A book that depends heavily on a small number of commercial payers, especially Medicare Advantage where denials have spiked the most aggressively, is a different asset than one with diversified exposure. The acquisition thesis is to buy concentration at a discount, then diversify through bolt-ons or contract renegotiation. The seller usually doesn't price the risk because they've lived with it for a decade.

Fourth, technology stack fragmentation. Most sub-$5M specialty RCM businesses run on three to five disconnected systems: a clearinghouse, an EHR-adjacent billing module, a separate denial management tool, manual eligibility verification, and spreadsheets bridging all of it. Sixty percent of executives have not implemented any AI or automation in their revenue cycle operations. Consolidation to a unified platform with predictive denial analytics is where post-close margin expansion lives, and where AI stops being a buzzword and starts being a measurable EBITDA lever.

Why this is a Deal Zero lane

The capital stack matches the asset. Specialty RCM businesses in the sub-$5M enterprise value range are SBA 7(a) financeable, which preserves equity for the larger platform deal that follows. They throw off contracted, recurring revenue, typically 4% to 7% of collected receipts, which underwrites debt service comfortably. The seller universe is heavily owner-operator: founders in their late 50s and 60s who built the book over fifteen to twenty years and have no internal succession.

The strategic logic compounds when you consider what a specialty RCM platform unlocks downstream. Crownestone Health Partners' broader thesis runs through behavioral health, DSO, diagnostics, home health and hospice, pharma services, healthcare staffing, and biotech services. Every one of those verticals depends on revenue cycle infrastructure. Owning the RCM layer first means owning a structural lens into deal flow across the rest of the healthcare services landscape, with the operational competence to underwrite targets in those verticals more accurately than buyers who don't.

The target profile

The criteria for a Deal Zero specialty RCM target are tight by design. EBITDA between $750K and $2.5M. Recurring revenue above 80% under multi-year client contracts. No single client above 25% of revenue. An established book in one or more high-denial specialties: anesthesia, ASC, orthopedic, pain management, behavioral health, GI, or radiology. Southeast US geographic anchor, remote-capable operations, and a seller motivated by retirement or partial liquidity rather than distress.

Diligence-critical metrics: clean claim rate, denial rate by category, net collection rate, cost-to-collect. Anything below a 95% clean claim rate is either a red flag or an acquisition thesis, depending on whether the buyer has the operational capability to fix it.

The play: buy specialty competence at generalist multiples, install AI-augmented denial prevention and unified analytics, expand margin through technology consolidation rather than headcount cuts, and use the platform as a structural advantage in the healthcare services M&A pipeline that follows.

A note on what this isn't

This is not a thesis about buying generalist billing shops at consolidation multiples and stripping cost. That trade is crowded and the returns have compressed. The mispricing lives specifically in specialty RCM, where operational complexity creates a moat generalist roll-ups cannot easily replicate. The buyers who win in this lane will be the ones who can credibly tell a specialty operator, in their own clinical and operational language, what their book is actually worth and what an integration plan looks like in the first 100 days.

That is an operator-buyer's edge, not a financial buyer's edge. Which is exactly why it remains mispriced.

If you operate a specialty RCM business in the Southeast and are considering succession options, Crownestone Health Partners is actively evaluating Deal Zero targets in this lane. Inbound conversations are confidential and bilateral.